Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

B Cell Targeted Treatment In Myasthenia Gravis (BeatMG): A Phase II Trial of Rituximab In Myasthenia Gravis

Next Previous
X
Search
Trial Profile

B Cell Targeted Treatment In Myasthenia Gravis (BeatMG): A Phase II Trial of Rituximab In Myasthenia Gravis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BeatMG

    • Most Recent Events

    • 09 Nov 2022 Results of pooled analysis from BeatMG and ADAPT trial assessing the efficacy of Efgartigimod vs Rituximab in adult patients with generalized myasthenia gravis (gMG) and autoantibodies against the acetylcholine receptor presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 02 Dec 2021 Results assessing the class I evidence that for mild-tomoderate AChR-Ab+ gMG, compared with placebo, rituximab is safe but unlikely to reduce steroid use by an absolute difference of at least 30% at 1 year, published in the Neurology.
    • 07 Sep 2018 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top